Monte Rosa Therapeutics (GLUE) Net Margin (2024 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Net Margin of 1036.07% for Q1 2026, down 109127.0% year-over-year from N/an in Q1 2025, and up 2.29% quarter-over-quarter from 1060.37% in Q4 2025.
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Net Margin (2024 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Net Margin history runs 3 years deep, the most recent figure standing at 1036.07% for Q1 2026.
- In Q1 2026, Net Margin fell 109127.0% year-over-year to 1036.07%; the TTM figure through Mar 2026 stood at 2637.58% (down 265228.0% YoY), while the FY2025 annual figure was 17.77%, up 5549.0% from the prior year.
- Net Margin for Q1 2026 stood at 1036.07%, up from 1060.37% in the prior quarter.
- The five-year high for Net Margin was 55.2% in Q1 2025, with the low at 3006.11% in Q1 2024.
- The 3-year median for Net Margin is 258.89% (2024), against an average of 658.66%.
- Peak annual rise in Net Margin reached 306131 bps in 2025, while the deepest fall reached 111105 bps in 2025.
- Monte Rosa Therapeutics' Net Margin stood at 50.68% in 2024, then tumbled by 2192 bps to 1060.37% in 2025, then rose by 2 bps to 1036.07% in 2026.
- Business Quant data shows GLUE's Net Margin at 1036.07% in Q1 2026, 1060.37% in Q4 2025, and 18.05% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -3.12% |
| 10 | Monte Rosa Therapeutics | 1.40 Bn | 771.57 Mn | - | -483.91% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -483.91% |
| Mar 31, 2026 | -1,058.22% |
| Dec 31, 2025 | -1,399.64% |
| Sep 30, 2025 | -212.10% |
| Jun 30, 2025 | -8.77% |
| Mar 31, 2025 | 55.20% |
| Dec 31, 2024 | 50.68% |
| Sep 30, 2024 | -258.89% |
| Jun 30, 2024 | -645.58% |
| Mar 31, 2024 | -3,006.11% |